Delving into the Latest Updates on Astrogen Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Other Diseases

Congenital Disorders

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Nervous System Diseases	7
Endocrinology and Metabolic Disease	2
Neoplasms	2

Top 5 Drug Type	Count

Small molecule drug	10

1. Study purpose: To demonstrate the superiority of AST-001 compared to placebo in improving core symptoms of autism spectrum disorder (ASD) in children with ASD.
2. Background: ASD is a neurodevelopmental disorder characterized by deficits in social communication and social interaction as well as restricted, repetitive patterns of behavior, interests, or activities. There are no approved medicines to treat the core symptom of ASD. Although these drugs and other psychotropic medications are associated with side effects, the use of psychotropic drugs to treat associated psychiatric comorbidities is common. AST-001 is developed to treat the core symptom of ASD.
3. Design: Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 clinical trial followed by an Open-Label Extension Treatment Period

Start Date29 Aug 2023

Sponsor / Collaborator

Astrogen Co., Ltd.Startup

KCT0007519 / CompletedPhase 2

A Multi-center, Randomized, Double-blind, Placebo-controlled, Therapeutic Exploratory, Phase II Clinical Trial for the Efficacy Investigation and Safety Evaluation of AST-001 in Children with Autism Spectrum Disorder

Start Date03 Feb 2021

Sponsor / Collaborator

Astrogen Co., Ltd.Startup

100 Clinical Results associated with Astrogen Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Astrogen Co., Ltd.

Login to view more data

100 Deals associated with Astrogen Co., Ltd.

Login to view more data

100 Translational Medicine associated with Astrogen Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

8

Preclinical

Phase 3 Clinical

1

3

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

AST-001(Astrogen)	Autism Spectrum Disorder More	Phase 3
AST-008(Astrogen)	Epilepsies, Myoclonic More	Preclinical
AST-030	Pulmonary Fibrosis More	Preclinical
AST-029	Parkinson Disease More	Preclinical
AST-003(Astrogen)	Autism Spectrum Disorder More	Preclinical